431 results on '"Gerstein, Hertzel"'
Search Results
2. Vaspin: A Novel Biomarker Linking Gluteofemoral Body Fat and Type 2 Diabetes Risk.
3. Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis
4. Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis
5. Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis
6. Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study
7. Glucose Intolerance in Pregnancy and Offspring Obesity in Late Adolescence
8. Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022;44:684–691
9. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes
10. HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
11. Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial
12. Comment on Hempe et al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. Diabetes Care 2015;38: 1067–1074
13. Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters
14. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes
15. Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort
16. Effect of Hypoglycemia on Brain Structure in People With Type 2 Diabetes: Epidemiological Analysis of the ACCORD-MIND MRI Trial
17. The Cross-sectional and Longitudinal Associations of Diabetic Retinopathy With Cognitive Function and Brain MRI Findings: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
18. Cognitive Function and the Risk for Diabetes Among Young Men
19. Diabetes Risk Among Overweight and Obese Metabolically Healthy Young Adults
20. Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37: 1360–1366
21. Response to Suissa and Azoulay. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37: 1360–1366
22. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD trial
23. Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the start (self-titration with apidra to reach target) study: a randomized noninferiority trial
24. Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial
25. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia
26. Short leg length, a marker of early childhood deprivation, is associated with metabolic disorders underlying type 2 diabetes: the promise cohort study
27. Creating Composite Indices From Continuous Variables for Research: The Geometric Mean
28. Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36: 2915–2922
29. HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
30. Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents
31. Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial
32. Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study
33. Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population: The EpiDREAM genetic study
34. Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events: The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE)
35. Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial
36. Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial
37. Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial.
38. Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes: An analysis of baseline data from the ORIGIN trial
39. Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes: Post hoc epidemiologic analysis of the ACCORD trial
40. Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit: The RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) trial
41. Effect of Computer-Generated Tailored Feedback on Glycemic Control in People With Diabetes in the Community: A randomized controlled trial
42. Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial
43. Adolescent Obesity and Early-Onset Type 2 Diabetes
44. ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study
45. Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study
46. The Effect of Oral Antidiabetic Agents on A1C Levels: A systematic review and meta-analysis
47. Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance
48. Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
49. Novel Biomarkers for Change in Renal Function in People With Dysglycemia
50. Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.